Hims & Hers Health, Inc. $HIMS Shares Sold by QRG Capital Management Inc.

Key Points

• QRG Capital Management Inc. reduced its stake in Hims & Hers Health by 3.7%, holding 180,836 shares valued at approximately $9 million after selling nearly 7,000 shares in the second quarter.
• Recent earnings reported $0.17 earnings per share, slightly below expectations, with revenue of $544.83 million up 72.6% year-over-year.
• Analysts' ratings for Hims & Hers Health show two Buy ratings, nine Holds, and three Sell ratings, with a consensus price target of $38.92.

QRG Capital Management Inc. decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 3.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 180,836 shares of the company's stock after selling 6,919 shares during the period. QRG Capital Management Inc. owned 0.08% of Hims & Hers Health worth $9,015,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of HIMS. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth approximately $30,000. UMB Bank n.a. increased its position in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Hims & Hers Health during the first quarter worth approximately $41,000. Larson Financial Group LLC increased its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after purchasing an additional 458 shares during the last quarter. Finally, Webster Bank N. A. increased its position in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company's stock worth $45,000 after purchasing an additional 630 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on HIMS shares. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial cut their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a research note on Saturday, September 27th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Price Performance

HIMS opened at $52.61 on Friday. The company has a fifty day simple moving average of $51.47 and a 200 day simple moving average of $47.25. The firm has a market cap of $11.89 billion, a price-to-earnings ratio of 65.77, a PEG ratio of 3.55 and a beta of 2.25. Hims & Hers Health, Inc. has a twelve month low of $16.69 and a twelve month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the firm's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $506,060.50. Following the completion of the sale, the insider directly owned 169,940 shares of the company's stock, valued at approximately $8,581,970. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Irene Becklund sold 8,410 shares of the firm's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $424,705.00. Following the sale, the insider directly owned 1,418 shares of the company's stock, valued at approximately $71,609. The trade was a 85.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,622,727 shares of company stock worth $83,566,691. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.